Prospera Financial Services Inc increased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 7.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,363 shares of the company’s stock after purchasing an additional 427 shares during the quarter. Prospera Financial Services Inc’s holdings in Zoetis were worth $1,097,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in ZTS. Evermay Wealth Management LLC boosted its stake in shares of Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 112 shares during the period. Worth Asset Management LLC purchased a new position in Zoetis in the first quarter worth $26,000. Pacifica Partners Inc. grew its stake in Zoetis by 76.9% in the 2nd quarter. Pacifica Partners Inc. now owns 161 shares of the company’s stock valued at $27,000 after purchasing an additional 70 shares during the period. Finally, Altshuler Shaham Ltd purchased a new stake in shares of Zoetis during the 2nd quarter valued at $29,000. 89.47% of the stock is owned by institutional investors.
Insider Buying and Selling at Zoetis
In other news, CEO Kristin C. Peck sold 13,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total value of $2,339,610.00. Following the transaction, the chief executive officer now owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $172.92, for a total value of $159,605.16. Following the completion of the transaction, the executive vice president now owns 23,588 shares in the company, valued at $4,078,836.96. The disclosure for this sale can be found here. Insiders sold a total of 25,674 shares of company stock valued at $4,627,465 in the last three months. Company insiders own 0.12% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 8th. HSBC initiated coverage on shares of Zoetis in a research report on Wednesday, September 6th. They set a “buy” rating and a $230.00 target price for the company. Stifel Nicolaus dropped their price objective on Zoetis from $205.00 to $195.00 and set a “buy” rating on the stock in a research note on Monday, October 30th. Argus raised their target price on Zoetis from $190.00 to $201.00 in a research report on Tuesday, September 19th. Finally, Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $220.25.
Check Out Our Latest Stock Analysis on ZTS
Zoetis Price Performance
Shares of NYSE ZTS opened at $169.32 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.16 and a current ratio of 3.87. Zoetis Inc. has a fifty-two week low of $140.76 and a fifty-two week high of $194.99. The stock has a market cap of $77.74 billion, a PE ratio of 34.41, a price-to-earnings-growth ratio of 2.75 and a beta of 0.83. The stock has a fifty day moving average of $173.37 and a 200-day moving average of $175.73.
Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Tuesday, August 8th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.10. Zoetis had a return on equity of 52.22% and a net margin of 27.24%. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.16 billion. During the same quarter in the previous year, the firm earned $1.20 EPS. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 5.41 earnings per share for the current year.
Zoetis Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Wednesday, November 1st will be paid a $0.375 dividend. This represents a $1.50 annualized dividend and a yield of 0.89%. The ex-dividend date is Tuesday, October 31st. Zoetis’s dividend payout ratio is presently 30.49%.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.